<DOC>
	<DOCNO>NCT00494039</DOCNO>
	<brief_summary>Objective : To test hypothesis short half-life Pd-103 versus I-125 , increase rate tumor eradication . Research design A total 600 patient AJC clinical stage T1c-T2a prostatic carcinoma ( Gleason grade 2 6 , PSA 4 10 ng/ml ) randomize implantation I-125 ( 160 Gy ) versus Pd-103 ( 115 Gy ) .</brief_summary>
	<brief_title>I-125 Versus Pd-103 Low Risk Prostate Cancer</brief_title>
	<detailed_description>Objective : To test hypothesis short half-life Pd-103 versus I-125 , increase rate tumor eradication . Research design A total 600 patient AJC clinical stage T1c-T2a prostatic carcinoma ( Gleason grade 2 6 , PSA 4 10 ng/ml ) randomize implantation I-125 ( 160 Gy ) versus Pd-103 ( 115 Gy ) . Methodology : Patients randomize method random permute block . Cancer status monitor serial serum PSA 6 , 12 , 18 24 month yearly thereafter . Treatment-related morbidity monitor personal interview , use standard American Urologic Association Radiation Therapy Oncology Group criteria 1 , 3 , 6 , 12 24 month . Patients serum PSA 1.0 ng/ml two year treatment consider residual recurrent cancer fail therapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Males age 4080 PSA 410 Gleason score 56 Lymph node positive</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>radiation</keyword>
	<keyword>brachytherapy</keyword>
</DOC>